Literature DB >> 84761

Significance of the acetylation phenotype and the therapeutic effect of procainamide.

P Schröder, N A Klitgaard, E Simonsen.   

Abstract

In order to estimate the relative anti-arrhythmic effect of procainamide and N-acetyl-procainamide, 18 randomly selected, patients with arrhythmia were divided into two groups; the first was treated with Pronestyl in the first half of the investigation period, followed by Duretter in the second half, and the second group began with Duretter and terminated with Pronestyl. The concentrations of procainamide and N-acetylprocainamide were measured twice a day during the steady state part of each treatment period. The acetylation phenotype of the patients was determined with sulfadimidine, and compared with the relative serum concentrations of procainamide and N-acetylprocainamide. N-acetylprocainamide was found to antagonize the action of procainamide.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 84761     DOI: 10.1007/BF00563559

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Polymorphic acetylation of procaine amide in healthy subjects.

Authors:  E Karlsson; L Molin
Journal:  Acta Med Scand       Date:  1975-04

2.  Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions.

Authors:  W K Lee; J M Strong; R F Kehoe; J S Dutcher; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

3.  Plasma levels of procaine amide after administration of conventional and sustained-release tablets.

Authors:  E Karlsson
Journal:  Eur J Clin Pharmacol       Date:  1973-12       Impact factor: 2.953

4.  A new sustained-release tablet formulation of procainamide.

Authors:  D Fremstad; S Dahl; S Jacobsen; P K Lunde; K J Nådland; A A Marthinsen; T Waaler; K H Landmark
Journal:  Eur J Clin Pharmacol       Date:  1973-12       Impact factor: 2.953

5.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

6.  Metabolism of procainamide in rhesus monkey and man.

Authors:  J Dreyfuss; J T Bigger; A I Cohen; E C Schreiber
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

7.  Absorption, excretion, and biotransformation of procainamide-C 14 in the dog and rhesus monkey.

Authors:  J Dreyfuss; J J Ross; E C Schreiber
Journal:  Arzneimittelforschung       Date:  1971-07

8.  Antiarrhythmic potency of N-acetylprocainamide.

Authors:  J Elson; J M Strong; W K Lee; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

9.  Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions.

Authors:  A J Atkinson; W K Lee; M L Quinn; W Kushner; M J Nevin; J M Strong
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

10.  Comparison of the acetylation of procainamide and sulfadimidine in man.

Authors:  K Frislid; M Berg; V Hansteen; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

View more
  4 in total

Review 1.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

Review 2.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

3.  Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.

Authors:  P Ylitalo; R Ruosteenoja; O Leskinen; T Metsä-Ketelä
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.